TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15723201
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 100% TTO
Study: 11772797
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg midazolam syrup
Study: 11772797
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg midazolam syrup
Study: 11772797
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg midazolam syrup
Study: 11772797
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg midazolam syrup (maximum 20 mg)
Study: 11772797
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of midazolam syrup
Study: 9674809
Drug: i.v. methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. methylprednisolone high dose
Study: 9674809
Drug: i.v. methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. methylprednisolone low dose
Study: 7988623
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg + 250 mg) + Midazolam 10 mg
Study: 7988623
Drug: Erythromycin 750
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 750 mg (as a positive control)
Study: 3052965
Drug: naproxen 10
Normalized name: naproxen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 10 mg/kg/day
Study: 3052965
Drug: tolmetin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolmetin 25 mg/kg/day
Study: 3052965
Drug: diclofenac 2
Normalized name: diclofenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 2 mg/kg/day
Study: 30384842
Drug: iv exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv exenatide (1‐h bolus of 0.05 µg min‐1 followed by a constant infusion of 0.025 µg min‐1)
Study: 30384842
Drug: iv insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv insulin therapy (control group)
Study: 24274806
Drug: Tailored interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored interventions (specific details on dosage and duration not provided)
Study: 21673137
Drug: Pasireotide 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 450 µg/d
Study: 21673137
Drug: Pasireotide 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 900 µg/d
Study: 21673137
Drug: Pasireotide 1350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 1350 µg/d
Study: 21673137
Drug: Pasireotide 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 1800 µg/d
Study: 21673137
Drug: Pasireotide 2250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 2250 µg/d
Study: 21673137
Drug: Pasireotide 2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 2025 µg/d
Study: 21673137
Drug: Pasireotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide infusion
Study: 16113179
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide as a slow intravenous infusion over 15 minutes (SIG group)
Study: 16113179
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide intravenous bolus infusion over two minutes (BIG group)
Study: 12107041
Drug: Acamprosate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate plus minimal intervention (3‐weekly sessions of 20 min)
Study: 12107041
Drug: Acamprosate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate plus brief cognitive behavioural therapy (7‐weekly sessions of 60 min)
Study: 2129490
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine b.d.
Study: 2129490
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen b.d. + 20 mg famotidine b.d.
Study: 2129490
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen b.d. + 40 mg famotidine nocte
Study: 2129490
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen b.d. + placebo
Study: 6160364
Drug: Gamma Venin
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma Venin 10 g within the first 48 h after surgery
Study: 31842966
Drug: Small stitches
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small stitches closure followed by augmentation with a light-weight polypropylene mesh in the onlay technique
Study: 27486122
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (2 RDAs daily for 6 months)
Study: 27486122
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (2 RDAs daily for 6 months)
Study: 27486122
Drug: Both vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vitamin B12 and folic acid supplementation (2 RDAs daily for 6 months)
Study: 27486122
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (daily for 2 months)
Study: 24994725
Drug: FRAX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRAX treatment criteria
Study: 24994725
Drug: Osteoporosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoporosis treatment
Study: 22611315
Drug: Small-volume epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small-volume epinephrine (15 to 25 mL injection; Group 1, n = 50)
Study: 22611315
Drug: Large-volume epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Large-volume epinephrine (30 to 40 mL injection; Group 2, n = 50)
Study: 17541049
Drug: Duloxetine, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine, 60 mg/day
Study: 9846847
Drug: High oleate
Normalized name: oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oleate meal (95 g fat)
Study: 9846847
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (18 g MCT)
Study: 7865062
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium (2 x ED 95)
Study: 7865062
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg rocuronium as priming dose followed by 0.24 mg/kg intubating dose
Study: 7865062
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (0.6 mg/kg and 0.06 mg/kg + 0.24 mg/kg)
Study: 2690557
Drug: Adjuvant single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant single-agent doxorubicin
Study: 30637662
Drug: 200 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg/day selenium supplements as selenium yeast (n=17)
Study: 29774682
Drug: Flupentixol/Melitracen 10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol/Melitracen 10.5 mg, QD, treatment lasts 4 months
Study: 29774682
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (specific immunotherapy only)
Study: 29774682
Drug: Flupentixol/Melitracen combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol/Melitracen combined with specific immunotherapy
Study: 25917673
Drug: bivalent OPV
Normalized name: Opvee
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bivalent OPV (bOPV) + inactivated polio vaccine (IPV)
Study: 23452344
Drug: Deep neuromuscular
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep neuromuscular blockade (NMB) using high-dose rocuronium, reversed by 4 mg/kg sugammadex
Study: 23452344
Drug: Moderate neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate neuromuscular blockade (NMB) using a combination of atracurium and mivacurium, reversed by 1 mg neostigmine and 0.5 mg atropine
Study: 17914039
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg per day
Study: 11510790
Drug: Conventional CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CPAP therapy
Study: 11510790
Drug: Auto CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto CPAP therapy
Study: 7646097
Drug: Completely heparin-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completely heparin-coated circuit with reduced heparin dose (activated clotting time > 250 seconds)
Study: 15169793
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m²
Study: 15169793
Drug: Paclitaxel 210
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 210 mg/m²
Study: 15169793
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg/m²
Study: 15169793
Drug: Paclitaxel (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (all doses)
Study: 15169793
Drug: Paclitaxel (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (higher doses)
Study: 9387047
Drug: Liposomally encapsulated
Normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liposomally encapsulated daunorubicin (DaunoXome) at 120 mg/m2 repeated every 21 days
Study: 9387047
Drug: Liposomally encapsulated
Normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liposomally encapsulated daunorubicin (DaunoXome) at 40 mg/m2 repeated every 14 days
Study: 8404181
Drug: Salt loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt loading (+ 6.1 +/‐ 2.8 g NaCl/d = + 105 +/‐ 48 mmol Na)
Study: 8404181
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate loading (+ 140 +/‐ 40 ml Shohl's solution, = + 120 +/‐ 30 mmol Na)
Study: 8404181
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (5 to 6 g NaCl/d = 86 to 103 mmol Na)
Study: 3528541
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg disulfiram
Study: 3528541
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg disulfiram
Study: 2645950
Drug: Repeated treatment
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated treatment with daunorubicin (DNR), vincristine (VCR), and cytosine arabinoside (ara‐C)
Study: 2645950
Drug: Alternating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating treatment with amsacrine (AMSA) combined with high dose ara‐C and 5-azacytidine
Study: 2645950
Drug: Intensive combination
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive combination of high-dose ara‐C and AMSA
Study: 21054754
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of udenafil given 1 h before TURP
Study: 21054754
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tadalafil given 1 h before TURP
Study: 11465985
Drug: Systemic adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic adenosine infusion (50 microg/kg/min for 60 min)
Study: 11465985
Drug: Systemic adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic adenosine infusion
Study: 8276659
Drug: 5-fluorouracil, 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil, 450 mg/m2 intravenously for 3 consecutive days during the first and last weeks of radiation therapy; Levamisole, 50 mg orally 3 times daily for 3 consecutive days concurrent with radiation therapy and 5-fluorouracil.
Study: 4844514
Drug: Quingestanol acetate
Normalized name: quinestradol
DrugBank: Quingestanol acetate (DB14679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quingestanol acetate (1.5 mg postcoital)
Study: 4844514
Drug: d‐norgestrel (3.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐norgestrel (3.35 mg postcoital)
Study: 24888428
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (rt-PA) for anterior circulation strokes in patients with LVO
Study: 24888428
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (rt-PA) for anterior circulation strokes in patients with No-LVO
Study: 21691117
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (20 mg/kg/day for 3 weeks)
Study: 9482363
Drug: Acetaminophen, aspirin,
Normalized name: Acetaminophen, Aspirin, and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, aspirin, and caffeine combination
Study: 7923517
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered to patients with HPT
Study: 7923517
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered to control patients
Study: 31830868
Drug: arts therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: arts therapies intervention
Study: 22920307
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (75 mg of clopidogrel in addition to 300 mg of aspirin)
Study: 22920307
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (300 mg of aspirin)
Study: 19702702
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (CsA) 0.05% ophthalmic emulsion twice daily and concomitant five times daily non-preserved artificial tear
Study: 19702702
Drug: Vehicle emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle emulsion twice daily and non-preserved artificial tear five times daily (Control)
Study: 17688611
Drug: ISMN‐SR 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISMN‐SR 60 mg vaginally
Study: 17688611
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 100 mg vaginally
Study: 7869468
Drug: Methadone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone plus 3 mg guanfacine
Study: 7869468
Drug: Methadone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone plus 4 mg guanfacine
Study: 3122549
Drug: Active nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nitroglycerin patch
Study: 27718280
Drug: Cervical pessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical pessary plus 400 mg daily vaginal progesterone (group B)
Study: 27718280
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily vaginal progesterone (group A)
Study: 24933496
Drug: Brief telephone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief telephone-based cognitive-behavioral therapy intervention
Study: 22513062
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% plus adrenaline 1:200,000 (group L)
Study: 15882226
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment based on instruction of proper prophylactic dental care
Study: 12563046
Drug: Selective head
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective head cooling with rectal temperature maintained at 35.0 degrees C
Study: 12563046
Drug: Selective head
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective head cooling with rectal temperature maintained at 34.5 degrees C
Study: 10668583
Drug: Cefepime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (1 g b.i.d.)
Study: 10668583
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 g t.i.d.)
Study: 8250520
Drug: Pentasa (mesalazine)
Normalized name: mesalamine Enema [Pentasa]
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentasa (mesalazine) 2 g/day
Study: 3472450
Drug: Oral salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral salt loading (normal diet + 200 mmol NaCl/day for 4 weeks followed by normal diet + 400 mmol/day for 1 week)
Study: 29380951
Drug: Low sex
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sex hormone condition (gonadotropin releasing hormone antagonist, aromatase inhibitor, and placebo gel)
Study: 29380951
Drug: Testosterone add‐back
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone add‐back condition (testosterone gel)
Study: 22566311
Drug: 15 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/d I-PHGG (fiber group)
Study: 17950101
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose with amino acids
Study: 17950101
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose without amino acids (control)
Study: 15677624
Drug: Chemotherapy following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy following resection
Study: 12121731
Drug: Botulinum A
Normalized name: Botulinum antitoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum A toxin (100 IU in 4 ml of 9% saline)
Study: 12121731
Drug: Lidocaine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (4 ml of 0.5%)
Study: 7662601
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide dinitrate (first dose)
Study: 7662601
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide dinitrate (second dose)
Study: 2811943
Drug: Systemic prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic prednisone (0.4 to 0.5 mg/kg for one month, gradually withdrawn over three months)
Study: 2811943
Drug: Radioiodine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine treatment alone
Study: 30286300
Drug: Sprint Interval
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sprint Interval Training (SIT) executed twice a week
Study: 28619114
Drug: smartphone-based monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: smartphone-based monitoring system including an integrated feedback loop and context-aware cognitive behavioral therapy (CBT) modules
Study: 21211064
Drug: Weekly reminder
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly reminder and motivational text messages
Study: 12939852
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of treatment, infarct location, and enzyme level
Study: 22369270
Drug: Hydroxychloroquine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine treatment
Study: 12451430
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg once daily for 11 days
Study: 1752602
Drug: Bromocriptine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (10 patients randomized to receive this treatment)
Study: 7234826
Drug: Tolmetin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin (2,000 mg/day)
Study: 28509517
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group (oral health promotion package including pamphlet, baby toothbrush, fluoride toothpaste 1,000 mg/L, trainer cup)
Study: 24816536
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (0.5 mg/kg)
Study: 24816536
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 µg/kg)
Study: 24816536
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 µg/kg)
Study: 22772951
Drug: High pretreatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pretreatment NLR that declined after treatment
Study: 15497667
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (clopidogrel bisulfate, 75 mg)
Study: 9443770
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bisoprolol daily for 8 weeks
Study: 9443770
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg captopril twice daily for 8 weeks
Study: 7946439
Drug: Fludarabine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine treatment
Study: 27520090
Drug: Blood loss
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood loss (BL) of 1000 ml
Study: 22739998
Drug: No epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: No epidural steroid injection (No-ESI)
Study: 20877623
Drug: rAd5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAd5 vaccine alone (1×10^10 or 1×10^11 particle units)
Study: 20877623
Drug: rAd5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAd5 vaccine alone
Study: 20877623
Drug: rAd5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAd5 vaccine alone or DNA prime - rAd5 boost
Study: 19035857
Drug: Annual screening
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual screening with PSA (abnormal >4.0 ng/mL) and DRE